Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2561-2569

  Cao, Shousong ^a   Durrani, Farukh A ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLSELENOCYSTEINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; LACTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN; PACLITAXEL; PNU 101440E; SELENIUM DERIVATIVE; SELENOMETHIONINE; SORBITOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYSTEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; ORGANOSELENIUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; SELENIUM; SELENOMETHIONINE; TIME FACTORS;

EID: 1842478439     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0268     Document Type: Article

References (57)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
3. Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 2000;60:3717-21.
4. Yin MB, Toth K, Cao S, et al. Involvement of cyclin D1-cdk5 overexpression and MCM3 cleavage in bax-associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model. Int J Cancer 1999;83:341-8.
5. Dong Y, Ganther H, Stewart C, Ip C. Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 2002;62:708-14.
6. Wang Z, Jiang C, Lu J. Induction of caspase-mediated apoptosis and cell cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002;34:113-20.
7. Sinha R, Medina D. Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. Carcinogenesis (Lond) 1997;18:1541-7.
8. Wang Z, Jiang C, Ganther H, Lu J. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK, and p38 MAPK Signaling. Cancer Res 2001;61:7171-8.
9. Seo Y, Kelley M, Smith M. Selenomethionine regulation of p53 by a Ref1-dependent redox mechanism. Proc Natl Acad Sci USA 2002;99: 14548-53.
10. Gudkov A. Converting p53 from a killer into a healer. Nat Med 2002;8:1196-8.
11. Baines A, Taylor-Parker M, Goulet A, Renaud C, Gerner E, Nelson M. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 2002;4:370-4.
12. Ip C, Shu Z, Thompson HJ, Lisk D, Ganther HE. Chemoprevention of mammary cancer with Se-allylselenocysteine and other selenoamino acids in the rat. Anticancer Res 1999;19:2875-80.
13. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54.
14. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. J Am Med Assoc 1996;276: 1957-63.
15. Ip C, Dong Y. Methylselenocysteine modulates proliferation and apoptosis biomarkers in premalignant lesions of the rat mammary gland. Anticancer Res 2001;21:863-7.
16. Lu J, Jiang C, Kaeck M, et al. Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50: 213-9.
17. Dong Y, Zhang H, Hawthorn L, Ganther H, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003;63:52-9.
18. Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG. Molecular and biochemical features of poly (ADP-ribose) metabolism. Mol Cell Biochem 1993;122:171-93.
19. Whitacre C, Berger N. Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase. Cancer Res 1997;57:2157-63.
20. Whitacre CM, Zborowska E, Willson JKV, Berger NA. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clin Can Res 1999;5:665-72.
21. Earnshaw W, Martins L, Kaufmann S. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424.
22. Wolf B, Green D. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999;274:20049-52.
23. Martin D, Bertino J, Koutcher J. ATP depletion plus pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. Cancer Res 2000;60:6776-83.
24. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-90.
25. Kim T, Jung U, Cho DY, Chung AS. Se-methylselenocysteine induces apoptosis through caspase activation in HL-60 cells. Carcinogenesis (Lond) 2001;22:559-78.
26. Reinhold U, Blitz H, Bayer W, Schimdt, K. Serum selenium levels in patients with malignant melanoma. Acta Derm Verereol 1989;69: 132-6.
27. Last K, Cornelius V, Delves T. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin's lymphoma. J Clin Oncol 2003;21:2335-41.
28. Glattre E, Thomassen Y, Lund-Larsen P, Theodorsen L, Aaseth J. Prediagnostic serum selenium in a case-control study of thyroid cancer. Int J Epidemiology 1989;18:45-9.
29. Jaskiewicz K, Marasas W, Rossouw J, Van Niekerk FE, Heine Tech EW. Selenium and other mineral elements in populations at risk for esophageal cancer. Cancer (Phila) 1988;62:2635-9.
30. Westin T, Ahlbom E, Johansson E, Sandstrom B, Karlberg I, Edstrom S. Circulating levels of selenium and zinc in relation to nutritional status in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1989;115:1079-82.
31. Hardell L, Degerman A, Tomic R, Marklund S, Bergfors M. Levels of selenium in plasma and glutathione peroxidase in erythrocytes in patients with prostate cancer or benign hyperplasia. Eur J Cancer Prev 1995;4:91-5.
32. Burney P, Comstock G, Morris J. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr 1989;49:895-900.
33. Gerhardsson L, Brune D, Nordberg I, Wester P. Protective effect of selenium on lung cancer in smelter workers. Br J Ind Med 1985;42: 617-26.
34. Miyamoto H, Araya Y, Ito M, et al. Serum selenium and vitamin E concentrations in families of lung cancer patients. Cancer (Phila) 1987; 60:1159-62.
35. Kawamori T, el-Bayoumy K, Ji B, Rodriguez J, Rao C, Reddy B. Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. Int J Oncol 1998; 13:29-34.
36. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima K. The effects of co-administration of selenium and cisplatin (CDDP) on CDDP-induced toxicity and antitumor activity. Br J Cancer 1988;58: 38-41.
37. Baldew GS, Mol JG, de Kanter FJ, van Baar B, de Goeij JJ, Vermeulen NP. The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol 1991;41:1429-37.
38. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis (Lond) 1999;20:1657-66.
39. Ip C, Lisk DJ, Ganther HE. Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. Anticancer Res 1998;18:4019-25.
40. El-Bayoumy K. The protective role of selenium on genetic damage and on cancer. Mutat Res 2001;475:123-39.
41. Greeder G, Milner J. Factors influencing the inhibitory effect of selenium on mice inoculated with Ehrlich ascites tumor cells. Science (Wash DC) 1980;209:825-7.
42. Poirer K, Milner J. Factors influencing the antitumorigenic properties of selenium in mice. J Nutr 1983;113:2147-54.
43. Lanfear J, Fleming J, Wu L, Webster G, Harrison P. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis (Lond) 1994; 15:1387-92.
44. Wu L, Lanfear J, Harrison P. The selenium metabolite selenodiglutathione induces cell death by a mechanism distinct from H2O2 toxicity. Carcinogenesis (Lond) 1995;16:1579-84.
45. Thompson H, Wilson A, Lu J, et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis (Lond) 1994;15:183-6.
46. Ronai Z, Tillotson J, Traganos F, et al. Effects of organic and inorganic selenium compounds on rat mammary tumor cells. Int J Cancer 1995;63:428-34.
47. Fico M, Poirer K, Watrach A, Watrach M, Milner J. Differential effects of selenium on normal and neoplastic canine mammary cells. Cancer Res 1986;46:3384-8.
48. Medina D, Lane H, Oborn C. Uptake and localization of selenium-75 in mammary epithelial cells lines in vitro. Cancer Lett 1982;15:301-10.
49. Medina D, Oborn C. Selenium inhibition of DNA synthesis in mouse mammary epithelial cell line YN-4. Cancer Res 1984;44:4361-5.
50. Cox R. Selenite: a good inhibitor of rat-liver DNA methylase. Biochem Int 1985;10:63-9.
51. Zhu Z, Kimura M, Itokawa Y, et al. Apoptosis induced by selenium in human glioma cell lines. Biol Trace Elem Res 1996;54:123-34.
52. Kawamori T, el-Bayoumy K, Ji B, Rodriguez J, Rao C, Reddy B. Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. Int J Oncol 1998;13: 29-34.
53. Tillotson J, Upadhyaya P, Ronai Z. Inhibition of thymidine kinase in cultured mammary tumor cells by the chemopreventive organoselenium compound, 1,4-phenylenebis(methylene) selenocyanate. Carcinogenesis (Lond) 1994;15:607-10.
54. Adler V, Pincus M, Posner S, Upadhyaya P, el-Bayoumy K, Ronai Z. Effects of chemopreventive selenium compounds on June N-kinase activities. Carcinogenesis (Lond) 1996;17:1849-54.
55. Fiala E, Staretz M, Pandya G, el-Bayoumy K, Hamilton S. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DAN cytosine methylation. Carcinogenesis (Lond) 1998;19:597-604.
56. Ip C, Thompson HJ, Ganther HE. Selenium modulation of cell proliferation and cell cycle biomarkers in normal and premalignant cells of the rat mammary gland. Cancer Epidemiol Biomark Prev 2000;9: 49-54.
57. Rao C, Simi B, Hirose Y, Upadhyaya P, el-Bayooumy K, Reddy B. Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet. Int J Oncol 2000;16:519-27.